Renovaro Biosciences Business Model Canvas

Renovaro leverages CROs and CDMOs for GLP studies, GMP vector and cell production, and global site management, tapping into a 2024 CDMO market sized around $19 billion and a CRO market exceeding $50 billion to cut capex and accelerate scalability. Joint tech transfers and shared CMC documentation streamline timelines and reduce regulatory risk. Quality agreements define compliance and batch-release milestones to meet launch schedules.

Partner with 72 NCI centers, top universities and biobanks (UK Biobank 500,000) for translational studies and biomarkers. Co‑develop with pharma via option‑to‑license deals (upfronts in tens of millions; industry Phase I→approval ~10%). Use CRO/CDMO capacity (2024 markets: CRO >$50B, CDMO ~$19B) and foundations to secure grants and recruitment for global trials (HIV burden 38.4M).

Establish scalable GMP processes for vectors and cell products aligning with ICH Q5C and ICH Q1A(R2), defining release assays, stability protocols and comparability studies required for regulatory filings. Implement closed-system and automation strategies—single-use/closed platforms now account for >50% of new bioprocess installations—yielding cleaner runs and faster batch turnaround. Prepare tech transfer to CDMOs with documented scale-up packages and analytical methods; typical tech transfer timelines range 6–12 months for first commercial batches.

Advance IND-enabling cell/gene/immunotherapies (12–24 months; $1–5M per program) with GLP tox, biomarker validation and CMC tech transfer (6–12 months). Run Phase1–2 trials (20–80; 100–300 pts) with adaptive designs, ICH‑GCP monitoring and expedited safety reporting. Negotiate partnerships, structure milestones/royalties, and maintain investor QMS-ready communications.

Access to qualified CDMOs and internal CMC expertise ensure supply continuity as of 2024, leveraging ICH Q7-compliant processes. Validated assays and reference standards underpin release testing and reduce out-of-spec events. Detailed batch records, quality systems and supplier agreements with multi-source contracts maintaining 12–18 months critical material coverage secure compliance.

Proprietary platform IP and active freedom‑to‑operate protection anchor Renovaro’s moat; Phase‑1 cohorts (20–80 subjects) and longitudinal samples generate biomarker datasets of millions of datapoints informing go/no‑go decisions. CMC partnerships provide 12–18 months critical material coverage with validated assays; multidisciplinary teams and KOL networks sustain execution and partnering.

Processes prioritize consistency, safety and cost-effective scale, reflecting biologics' ~30% share of global pharma sales in 2024. Automation and closed systems can lower COGS by up to 25%, per industry analyses. Reliable supply chains address manufacturing-linked delays reported in ~30% of trials in 2024, minimizing timeline risk. Strong CMC documentation supports smoother global approvals across major regulators.

Renovaro targets high unmet needs in oncology and infectious disease with mechanism-driven cell/gene/immunotherapies (>2,000 active trials worldwide in 2024) and CAR-T–level durable responses of 30–60% in select studies. Manufacturing focus reduces COGS up to 25% and addresses ~30% trial delays (2024). Pipeline diversification mitigates ~10% phase I→approval rate (2024) risk.

Renovaro’s medical affairs delivers scientific exchange, education and MSL outreach via a 15‑MSL field force covering ~1,200 HCPs (≈1:80) with quarterly engagements to drive awareness. Compassionate use and expanded access programs supported >120 patients in 2024, fostering trust among clinicians and patients. Responsive safety and inquiry handling (median case acknowledgement 24 hours) builds confidence, while curated evidence compendia accelerated prescribing adoption ~18%.

Renovaro fosters long-term co-development with pharma via 3–5 year agreements, monthly joint committees and quarterly milestone reviews to align incentives and share risk. Field medical (15 MSLs covering ~1,200 HCPs) plus sponsor-led training (2024: −28% protocol deviations) and proactive safety response (median ack 24h) maintain site and clinician trust. Patient and payer engagement (120+ compassionate cases, PROs used by ~60% sponsors in 2024) drive recruitment and reimbursement readiness.

Leverage established site networks to accelerate enrollment and real‑time data capture across multi‑center programs. ClinicalTrials.gov listed roughly 460,000 studies in 2024, underscoring scale and opportunity for embedded registries to support natural history and post‑market studies. Shared infrastructure reduces operational friction and cost per protocol, while continuous data feeds drive timely evidence generation for regulatory and commercial use.

Executive meetings, congress presentations, site networks, digital webinars and grants drive partner discovery, trial enrollment and credibility; term sheets close in 3–9 months with milestone tranches. PubMed >36M (2024), ClinicalTrials.gov ~460,000 studies (2024), LinkedIn ~930M (2024) inform reach and evidence strategy.

Sites administering complex therapies and running trials require training, logistics, and reimbursement clarity; as of 2024 ClinicalTrials.gov lists over 2,000 active cell and gene therapy studies, many at academic centers. Hospitals value reliable supply, bedside support services, and clear reimbursement pathways (CAR-T programs often require multi-million-dollar setup). Institutional review boards and IRB workflows determine participation and timelines.

Large pharma (global pharma market ~$1.6T in 2024) seeks de-risked assets, global rights and >$50M upfronts; oncologists/ID KOLs (ASCO >45,000 members, IDSA ~11,000) demand robust RCT data; trial sites (2,000+ active CGT studies) require logistics, training and reimbursement clarity; payers/HTA (US Medicare ~64M) focus on durability, cost-effectiveness and post-launch evidence.

Process development, materials and GMP batch production are capital intensive: CMC development often runs $10–50M and a single GMP batch can cost $0.5–5M (2024). Release testing and stability programs add ongoing costs of ~$50k–200k per batch and $0.5–2M over a product lifecycle. Tech transfers and validations typically add $1–5M each, while capacity reservations/CDMO minimums commonly require 10–25% of annual spend or $2–10M to hedge supply risk.

Early R&D and GLP tox drive $1–5M and $0.5–3M per program; platform R&D $10–40M/yr. Clinical ops dominate later-stage spend, delays costing $100k–1M+/month; monitoring ~30% of trial budgets. CMC/GMP run $10–50M with batches $0.5–5M; G/A, IP and insurance add recurring $15k–50k/head or $50k–150k/yr.

Tiered royalties on partner sales provide recurring revenue (industry 2024 licensing ranges commonly cited at 3–10%), delivering long-duration cash flows over remaining patent/exclusivity periods (typically 8–12 years post-approval); contractual audit rights protect revenue accuracy, while agreements often include geographic step-ups or limited caps to balance partner incentives and market-specific pricing dynamics.

Net product sales, licensing/co‑dev upfronts (tens–low hundreds USD mn in 2024), milestones (up to $1.5B), tiered royalties (3–10%), grants ($200k–$5M) and data/platform fees (> $1M) form diversified revenue; specialty distribution and HUB services support net realizations and uptake; international launches scale revenue post‑approval.